Open Access

A comparison of perioperative outcomes of Video-Assisted Thoracic Surgical (VATS) Lobectomy with open thoracotomy and lobectomy: Results of an analysis using propensity score based weighting

  • Walter J Scott1Email author,
  • Ronald S Matteotti1,
  • Brian L Egleston1,
  • Salewa Oseni1 and
  • James F Flaherty1
Annals of Surgical Innovation and Research20104:1

DOI: 10.1186/1750-1164-4-1

Received: 12 November 2009

Accepted: 22 March 2010

Published: 22 March 2010

Abstract

Background

Randomized trials comparing VATS lobectomy to open lobectomy are of small size. We analyzed a case-control series using propensity score-weighting to adjust for important covariates in order to compare the clinical outcomes of the two techniques.

Methods

We compared patients undergoing lobectomy for clinical stage I lung cancer (NSCLC) by either VATS or open (THOR) methods. Inverse probability of treatment weighted estimators, with weights derived from propensity scores, were used to adjust cohorts for determinants of perioperative morbidity and mortality including age, gender, preop FEV1, ASA class, and Charlson Comorbidity Index (CCI). Bootstrap methods provided standard errors. Endpoints were postoperative stay (LOS), chest tube duration, complications, and lymph node retrieval.

Results

We analyzed 136 consecutive lobectomy patients. Operative mortality was 1/62 (1.6%) for THOR and 1/74 (1.4%) for VATS, P = 1.00. 5/74 (6.7%) VATS were converted to open procedures. Adjusted median LOS was 7 days (THOR) versus 4 days (VATS), P < 0.0001, HR = 0.33. Adjusted median chest tube duration (days) was 5 (THOR) versus 3 (VATS), P < 0.0001, HR = 0.42. Complication rates were 39% (THOR) versus 34% (VATS), P = 0.61. Adjusted mean number of lymph nodes dissected per patient was 18.1 (THOR) versus 14.8 (VATS), p = 0.17.

Conclusions

After balancing covariates that affect morbidity, mortality and LOS in this case-control series using propensity-weighting, the results confirm that VATS lobectomy is associated with a statistically significant shorter LOS, similar mortality and complication rates and similar rates of lymph node removal in patients with clinical stage I NSCLC.

Introduction

The routine use of video-assisted thoracic surgical (VATS) lobectomy for the treatment of resectable non-small cell lung cancer (NSCLC) remains controversial. Data supporting the use of VATS lobectomy come from randomized trials [14], a multicenter phase II study [5], case-control series and large retrospective series [6]. Meta-analyses have recently been published [7, 8]. The randomized trials enrolled relatively small numbers of patients and retrospective case series are subject to selection biases. Other recent publications have been case-control series [9, 10].

Most case-control techniques attempt to decrease the effect of selection bias when comparing two non-randomized treatment groups by analyzing patients that are "matched" based on preoperative variables that are known to affect the outcomes that are being studied. It can be difficult to find appropriate control patients for a case matching study unless a large control population is available. Even then, cases without an appropriate match in either the control or treatment groups are not usable for analysis. At times, eliminating the cases that cannot be matched may actually result in an increase in selection bias, casting doubt on the conclusion that differences in outcomes between the two groups are due to treatment effects [11].

Propensity score based weighting is a rigorous statistical technique for making nonrandomized comparisons that in theory allows all of the patient data to be used from two treatment groups. We used this method to adjust for selection differences between two patient populations with clinical stage I NSCLC who underwent lobectomy performed through either an open or VATS technique. We then compared the perioperative outcomes of the two adjusted groups.

Methods

Approval for this retrospective data analysis of prospectively collected data was obtained from the Institutional Review Board. Patients with known or suspected clinical stage I NSCLC who underwent surgical resection at Fox Chase Cancer Center (FCCC) during two periods of time, from mid-2003 until November, 2005 and from November 2005-through 2008 were analyzed. Patients undergoing lobectomy, bilobectomy or segmentectomy were included. During the study periods, patients underwent standard preoperative staging with chest computed tomography (CT) and positron emission tomography with CT (PET/CT). At the time of the study, brain MR was performed in patients with neurologic symptoms or for patients with T2 tumors. Cervical mediastinoscopy was performed selectively for patients with abnormal lymph nodes on any imaging study, or for those with T2 or more central tumors.

All of the operations in this series were performed by a single surgeon (WJS). Standard anesthetic management with single lung ventilation including restriction of intraoperative fluids was used in all patients. Open thoracotomy (THOR) was most commonly performed through a posterolateral incision with entry into the chest through the fifth intercostal space. Resection of a small portion of the 6th rib was routine. Muscle sparing incisions were used occasionally and rib resection was not performed in those instances. VATS lobectomy (VATS) was performed using three incisions, a 5 cm or smaller access thoracotomy and two additional 1 cm incisions. Rib spreading and rib resection were not performed. Visualization was achieved using the video thoracoscope.

Lymph node dissection was routinely performed in all cases (THOR or VATS). Postoperative pain control was achieved using patient-controlled analgesia delivered through thoracic epidural catheters (PCEA) or through the use of patient-controlled intravenous narcotics (PCA). Most recently, pain control for VATS lobectomies consists of PCA narcotics supplemented with a continuous local anesthetic infusion (0.2% ropivacaine) though subpleural catheters placed intraoperatively. Patients converted from VATS to thoracotomy were included in the VATS group. All complications were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 [12].

Patients undergoing thoracotomy (open cases) were the control population and patients undergoing VATS procedures comprised the treatment group. The baseline characteristics of the two groups are shown in table 1 (demographics). The endpoint of the study was postoperative length of stay (LOS), duration of chest tube placement, and overall complication rates. Because this was a nonrandomized comparison of two treatments, the two groups were adjusted for characteristics that were known to influence the main study outcomes. We chose age, sex, the preoperative FEV1 percent predicted and two additional measures, the Charlson Comorbidity Index (CCI) and the American Society of Anesthesiology (ASA) score. (Table 2) The CCI consists of the sum of weighted scores for 19 medical conditions that have been shown to affect mortality. The CCI has been validated in a surgical population of lung cancer patients [13]. The ASA score is a rating scale used by anesthesiologists to estimate the overall condition of a patient in the preoperative period Table 3[14].
Table 1

Charlson Comorbidity Index (CCI)

Score

Condition

1

Coronary artery diseasea

Congestive heart failure

Chronic pulmonary disease

Peptic ulcer disease

Peripheral vascular disease

Mild liver disease

Cerebrovascular disease

Connective tissue disease

Diabetes mellitus

Dementia

2

Hemiplegia

Moderate to severe renal disease

Diabetes with end-organ damage

Any prior tumor (within 5-years of diagnosis)b

Leukemia

Lymphoma

3

Moderate to severe liver disease

6

Metastatic solid tumor AIDS (not only HIV positive)

Adapted from Birim O, EJCTS 2003 with permission

Table 2

Patient Characteristics, Unadjusted data, % or mean (SD)

 

Thoracotomy

n = 62

VATS

n = 74

p-value

Male

47%

30%

0.054

FEV1% pred

79 (19)

85 (19)

0.040

CCI

1.7 (1.3)

1.7 (1.3)

0.982

Age

65 (10.3)

67 (10.9)

0.489

ASA

2.3 (0.6)

1.8 (0.7)

<0.001

Table 3

American Society of Anesthesiologist (ASA) Score

Class 1

Healthy patient, no medical problems

Class 2

Mild systemic disease

Class 3

Severe systemic disease, but not incapacitating

Class 4

Severe systemic disease that is a constant threat to life

Class 5

Moribund, not expected to live 24 hours irrespective of operation

An e is added to the status number to designate an emergency operation.

An organ donor is usually designated as Class 6

In order to adjust for baseline differences between those patients who did and did not have VATS, we used propensity score based adjustment through propensity score based weighting [15]. Similar propensity score based weighting has been used in a variety of settings to investigate treatment effects using observational data [16, 17]. The propensity scores, which are the probabilities of receiving VATS given potential confounders of treatment assignment, were estimated by a multiple logistic regression. The adequacy of the propensity score model was verified by examining adjusted differences in potential confounder variables between the treatment groups. The lack of significant differences in propensity-score adjusted averages of the confounder variables suggested that they could not be confounders after adjustment.

We used Fisher's exact tests and T-tests to assess unadjusted differences. For inferences concerning length of stay and time until chest tube removal, we used Cox proportional hazards regressions weighted by the inverse of the probability of receiving the treatment actually received. The weight would be the inverse of the propensity score for those in the VATS group and the inverse of one minus the propensity score for those in the thoracotomy group. The bootstrap [18] with 2500 resamples was used to calculate the standard errors. Cox models were used for the time to event variables since some patients were lost to follow-up (for example, discharged with a chest tube) and hence had censored data. We used simple linear regressions similarly weighted by the inverse of the probability of receiving the treatment actually received for adjusted inferences concerning the number of lymph nodes removed and the number of lymph node stations sampled. We used propensity score based weighted logistic models for adjusted inferences concerning complication rate differences.

Results

The study population consisted of 136 patients with clinical stage I NSCLC. There were 62 patients from 2003 through late-2005 who underwent lobectomy performed through an open thoracotomy and 74 patients who underwent VATS lobectomy from late 2005 through mid-2008. Patient demographics are shown in Table 1. There were more men in the group undergoing thoracotomy and the VATS group had slightly better pulmonary function based on preoperative FEV1 (% predicted). There were no significant differences between groups with respect to clinical stage, pathologic stage and histology (Table 4). There were no significant differences between groups with respect to the type of lobectomy performed (Table 4). Conversion of a VATS lobectomy to an open procedure occurred in 3/74 (4%) of patients. This generally involved enlargement of the access thoracotomy and placement of a small retractor, and then performance of the lobectomy with standard techniques. These patients were included in the VATS group for the purpose of analysis.
Table 4

Details of Surgical Procedures

 

Open lobe (n = 62)

 

VATS lobe (n = 74)

 

P value

Histology

     

Adeno

44

71%

50

68%

0.898

Squamous

9

15%

12

16%

 

Other

9

15%

12

16%

 

Clinical stage

     

IA

49

79%

65

88%

0.242

IB

13

21%

9

12%

 

Pathologic stage

     

IA

32

52%

45

61%

0.165

IB

20

32%

12

16%

 

II

5

8%

7

9%

 

III, IV

5

8%

10

14%

 

Type of resection

     

RUL

20

32%

23

31%

0.168

RML

3

5%

10

14%

 

RLL

8

13%

12

16%

 

LUL

18

29%

14

19%

 

LLL

10

16%

10

14%

 

Bilobectomy

3

5%

1

1%

 

Segmentectomy

0

0%

4

5%

 
Adjusting for observable differences between cohorts and balancing important covariates using propensity-score weighting resulted in two well-matched groups for analysis (Table 5). The perioperative results and analyses were based on comparison of data from the adjusted groups. Patients undergoing VATS lobectomy had a shorter length of stay (VATS, 4 days versus THOR, 7 days, p < 0.001, HR = 0.33 in favor of VATS). Patients in the VATS group also had their chest tubes removed earlier (VATS, 3 days versus THOR, 5 days, p < 0.0001, HR = 0.42 in favor of VATS). The number of lymph node stations dissected in the VATS and THOR groups was similar (4.6 stations versus 4.3 stations, respectively, p = 0.31) as was the total number of lymph nodes examined in the specimen (18.1 versus 14.8, p = 0.17). Mortality rates were similar, with 1/74 (1.4%) in the VATS group and 1/62 (1.6%) in the THOR group (p = 1.00).
Table 5

Patient Characteristics Adjusted Data, N = 136

 

Thoracotomy

n = 62

VATS

n = 74

Male

40%

39%

FEV1% pred

80 (19)

81 (20)

CCI

1.6 (1.3)

1.7 (1.3)

Age

66 (10)

66 (11)

ASA

2.1 (0.6)

2.1 (0.7)

Perioperative and postoperative complications were classified and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Table 6). No differences in complication rates were noted for either cohort (VATS or THOR). No complications were recorded for 40/62 (65%) THOR patients compared to 52/74 (70%) of VATS patients (p = 0.61). There was a trend suggesting a decrease in pulmonary complications in the VATS group 10/74 (14%) compared to the THOR group 20/62 (32%) (p = 0.10). Continuous heart rate monitoring was routine during the second period of the study when VATS lobectomy was initiated. Therefore the low number of arrhythmias in the THOR patients may reflect the fact that only those arrhythmias that were persistent or were associated with symptoms were recorded for those patients, whereas even brief periods of atrial fibrillation were detected and recorded for the VATS group.
Table 6

Complication Rates

Complication

Open N = 62

Unadjusted data

VATS N = 74

Unadjusted data

P value (unadjusted)

P value

(adjusted)

None

40 (65%)

52 (70%)

0.58

0.61

Pulmonary

20 (32%)

10 (14%)

0.01

0.10

Cardiac-arrhythmia

2 (3%)

10 (14%)

0.07

0.71

Hemorrhage

1 (2%)

4 (5%)

0.38

0.88

Other

1 (2%)

2 (3%)

1.00

0.98

When complications were examined by age (70 years and older){Table 7), the trend toward a decrease in pulmonary complications associated with VATS was present but still did not reach statistical significance, perhaps because of the small number of patients in each group.
Table 7

Complication rates in patients aged 70 and older

Complication

Open N = 22

VATS N = 30

P value (adjusted)

None

14 (64%)

21 (70%)

0.77

Pulmonary

7 (32%)

3 (10%)

0.08

Cardiac-arrhythmia

2 (9%)

5 (17%)

0.69

Hemorrhage

0 (0%)

1 (3%)

1.00

Other

0 (0%)

1 (3%)

1.00

Discussion

We used propensity score based weighting to perform a non-randomized comparison of patients who underwent wither open thoracotomy and lobectomy or VATS lobectomy for clinical stage I NSCLC. The statistical method that we used generates an adjusted population of patients whose outcomes are slightly different that the observed data. For example, that is the reason that the complication rates in Table 8 (39% for THOR and 34% for VATS) are slightly different than the unadjusted complication rates in Table 6 (35% for THOR and 30% for VATS). The adjusted rates are based on a larger number of patients and therefore should be considered the most generalizable data. After balancing the two cohorts based on preoperative covariates known to influence perioperative outcomes using propensity score based weighting, we found that patients undergoing VATS lobectomy for clinical stage I NSCLC had their chest tubes removed earlier (adjusted median 3 days versus 5 days, p < 0.001) and also had a shorter postoperative length of stay (adjusted median 4 days versus 7 days, p < 0.001)) than patients undergoing open thoracotomy. This is consistent with what others have observed from case control series [9, 10] and large retrospective case series [6]. Patients undergoing VATS lobectomy may experience less pain, have improved respiratory mechanics, and develop less of an inflammatory response compared to open thoracotomy, all of which combined may lead to a decreased postoperative length of stay.
Table 8

Perioperative Results, Adjusted Data

Op.

N

Peri-op mortality

(%)

Length of Stay

(Adjusted median days)

Chest tube removal (Adjusted median days)

Adverse Events (Adjusted % of patients with at least one)

Lymph Node Stations (Adjusted # sampled/patient)

Lymph Nodes (Adjusted mean # removed/patient)

Thor

62

1 (1.6%)

7

5

39%

4.6

18.1

VATS

74

1 (1.4%)

4

3

34%

4.3

14.8

  

P = 1.00

HR = 0.33

HR = 0.42

   

P-value

  

P < 0.0001

P = 0.0001

P = 0.61

P = 0.31

P = 0.17

Despite the marked reduction in postoperative length of stay, we found no statistically significant difference in overall complication rates or specific complication rates between VATS patients and THOR patients. One reason for this is that the number of episodes of atrial fibrillation in the THOR group was probably underestimated since routine use of postoperative heart rhythm monitoring was phased in during the first part of the study when the open lobectomy operations were performed. Therefore, it is likely that episodes of atrial fibrillation in this group were missed and that the true rate of atrial fibrillation in this group was much higher. This would have increased the overall and arrhythmia complication rates in the THOR group. Other studies have suggested that atrial fibrillation rates after VATS lobectomy are not different than after thoracotomy and lobectomy [8, 9].

Mortality rates were not different between groups in our study. We did observe a trend (p = 0.10) toward a decrease in respiratory complication rates in the VATS patients, especially in the 70 year and older group, with the rates of respiratory complications decreasing from 32% in the open group to 10% in the VATS group (p = 0.08). A decrease in respiratory complications in older patients undergoing VATS lobectomy compared to THOR was observed by Cattaneo et al. [10]. It is possible that a statistically significant difference in respiratory complication rates would have been observed in our study if the sample size had been larger.

Regarding oncologic efficacy of VATS compared to THOR, we found that all patients underwent compete resections with negative margins. The number of lymph node stations that were dissected and the total number of lymph nodes retrieved were similar for each group. Continued follow up will be required to determine oncologic efficacy of VATS compared to THOR.

The limitations of this study include its retrospective nature, the fact that management changes may have occurred over the study period that were not appreciated or reflected in the analysis (such as the change to continuous heart rate monitoring or other changes in postoperative management), and the sample size. The fact that is not a multicenter study is mitigated by the fact that our conclusions, while analyzed somewhat differently, are similar to those of other authors. The strengths of the study include the fact that all cases were performed by a single surgeon, it is a consecutive case series, and that covariates were balanced between the two cohorts using sophisticated statistical analysis.

Conclusion

In summary, we found that patients undergoing VATS lobectomy were able to have their chest tubes removed sooner and were discharged sooner after undergoing lobectomy for clinical stage I NSCLC than patients who underwent thoracotomy and lobectomy for the same indications. A trend toward a decrease in pulmonary complications in the VATS group was also observed, especially in patients 70 years of age or older. The use of propensity score-based weighting in this series and its application to larger databases will allow clinicians to draw stronger conclusions about the relative merits of VATS lobectomy versus open thoracotomy and lobectomy in the treatment of the patient with early stage lung cancer.

Abbreviations

ASA: 

American Society of Anesthesiologists

CCI: 

Charlson comorbidity index

CT: 

computed tomography

CTC: 

common toxicity criteria

FCCC: 

Fox Chase Cancer Center

FEV1: 

forced expiratory volume at 1 second

HR: 

hazard ratio

LOS: 

length of stay

MR: 

magnetic resonance

NCI: 

national cancer institute

NSCLC: 

non-small cell lung cancer

PCA: 

patient-controlled analgesia

PCEA: 

patient-controlled epidural analgesia

PET/CT: 

Positron emission tomography and computed tomography

THOR: 

open thoracotomy and lobectomy

VATS: 

video-assisted thoracic surgery.

Declarations

Acknowledgements

This Research supported in part by NIH grants P30 CA 06927 and an appropriation from the Commonwealth of Pennsylvania.

Portions of this work were presented at the 74th Annual Meeting of the American College of Chest Physicians, Philadelphia, PA, October 29, 2008.

Authors’ Affiliations

(1)
Fox Chase Cancer Center

References

  1. Kirby TJ, Mack MJ, Landreneau RJ, et al.: Lobectomy-video-assisted thoracic surgery versus muscle-sparing thoracotomy: a randomized trial. J Thorac Cardiovasc Surg 1995, 109: 997–1002. 10.1016/S0022-5223(95)70326-8View ArticlePubMedGoogle Scholar
  2. Sugi K, Kaneda Y, Esato K: Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis inpatients with clinical stage IA lung cancer. World J Surg 2000, 24: 27–31. 10.1007/s002689910006View ArticlePubMedGoogle Scholar
  3. Craig SR, Leaver HA, Yap PL, Pugh GC, Walker WS: Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg 2001, 20: 455–63. 10.1016/S1010-7940(01)00841-7View ArticlePubMedGoogle Scholar
  4. Shigemura N, Akashi A, Nakagiri T, Ohta M, Matsuda H: Complete vs. assisted thoracoscopic approach: a prospective randomized trial comparing a variety of video-assisted thoracoscopic lobectomy techniques. Surg Endosc 2004, 18: 1492–7. 10.1007/s00464-003-8252-4View ArticlePubMedGoogle Scholar
  5. Swanson S, et al.: Video-Assisted Thoracic Surgery Lobectomy: Report of CALGB 39802--A Prospective, Multi-Institution Feasibility Study. J Clin Oncol 2007, 25: 4993–4997. 10.1200/JCO.2007.12.6649View ArticlePubMedGoogle Scholar
  6. Mckenna RJ, Houch W, Fuller CB: Video-Assisted Thoracic Surgery Lobectomy: Experience with 1,100 Cases. Ann Thorac Surg 2006, 81: 421–6. 10.1016/j.athoracsur.2005.07.078View ArticlePubMedGoogle Scholar
  7. Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA: Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008, 86: 2008–16. 10.1016/j.athoracsur.2008.07.009View ArticlePubMedGoogle Scholar
  8. Yan TD, Black D, Bannon PG, McCaughan BC: Systematic review and meta-analysis of randomized and non-randomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-call lung cancer. J Clin Oncol 2009, 27: 2553–2562. 10.1200/JCO.2008.18.2733View ArticlePubMedGoogle Scholar
  9. Park BJ, Zhang H, Rusch VW, Amar D: Video-assisted thoracic does not reduce the incidence of postoperative atrial fibrillation after pulmonary lobectomy. J Thorac Cardiovasc Surg 2007, 133: 775–9. 10.1016/j.jtcvs.2006.09.022View ArticlePubMedGoogle Scholar
  10. Cattaneo SM, Park BJ, Wilton AS, Seshan VE, Bains MS, Downey RJ, et al.: Use of Video-Assisted Thoracic Surgery for Lobectomy in the Elderly Results in Fewer Complications. Ann Thorac Surg 2008, 85: 231–6. 10.1016/j.athoracsur.2007.07.080View ArticlePubMedGoogle Scholar
  11. Blackstone EH: Comparing apples and oranges. JThorac Cardiovasc Surg 2002, 123: 8–15. 10.1067/mtc.2002.120329View ArticleGoogle Scholar
  12. [http://ctep.cancer.gov/reporting/ctc.html]
  13. Birim O, Maat APWM, Kappetein AP, Van Meerbeck JP, Damhuis RAM, Rogers AJJC: Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg 2003, 23: 30–34. 10.1016/S1010-7940(02)00721-2View ArticlePubMedGoogle Scholar
  14. Cullen DJ, Apolone G, Greenfield S, Guadagnoli E, Cleary P: ASA Physical Status and age predict morbidity after three surgical procedures. Ann Surg 1994, 220: 3–9.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Lunceford JK, Davidian M: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Statistics in Medicine 2004, 23: 2937–2960. 10.1002/sim.1903View ArticlePubMedGoogle Scholar
  16. Sterne JAC, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005, 366: 378–384. 10.1016/S0140-6736(05)67022-5View ArticlePubMedGoogle Scholar
  17. MacKenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Frey KP, Egleston BL, Salkever DS, Scharfstein DO: A national evaluation of the effect of trauma-center care on mortality. N Eng J Med 2006, 354(4):366–378. 10.1056/NEJMsa052049View ArticleGoogle Scholar
  18. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. Boca Raton, FL; Chapman & Hall/CRC; 1994.Google Scholar

Copyright

© Scott et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement